NSCLC with uncommon EGFR mutations treated with atezolizumab plus bevacizumab and chemotherapy. Trummer A, Bethge A, Dickgreber N, Dittrich I, et al. Lung Cancer 2022;174:141-145.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Trummer A, Bethge A, Dickgreber N, Dittrich I, et al. NSCLC with uncommon EGFR mutations treated with atezolizumab plus bevacizumab and chemotherapy. Lung Cancer 2022;174:141-145.
PMID: 36402005